Detalhe da pesquisa
1.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Lancet Oncol
; 25(4): 474-487, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547892
2.
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Int J Cancer
; 154(4): 701-711, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37831416
3.
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
Oncologist
; 29(3): 213-218, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38070191
4.
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Breast Cancer Res Treat
; 204(2): 289-297, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38155272
5.
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
Future Oncol
; : 1-9, 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38536033
6.
Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
Future Oncol
; : 1-9, 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517416
7.
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Oncologist
; 28(10): 866-874, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487056
8.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 199(3): 457-469, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061619
9.
Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary.
Future Oncol
; 19(7): 489-498, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892508
10.
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Int J Cancer
; 150(12): 2025-2037, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133007
11.
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
Breast Cancer Res Treat
; 193(2): 253-264, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347549
12.
Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement.
Ann Surg Oncol
; 29(10): 6381-6392, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35834145
13.
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
Breast Cancer Res
; 23(1): 37, 2021 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761995
14.
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Oncologist
; 25(8): e1158-e1169, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452601
15.
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
BMC Cancer
; 20(1): 430, 2020 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32423453
16.
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
BMC Cancer
; 20(1): 445, 2020 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32429929
17.
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
Breast J
; 26(8): 1572-1582, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497289
18.
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Invest New Drugs
; 41(3): 391-401, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043123
19.
ASO Visual Abstract: Long-Term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement.
Ann Surg Oncol
; 29(Suppl 3): 620-621, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104531
20.
Breast Cancer Risk Reduction, Version 2.2015.
J Natl Compr Canc Netw
; 13(7): 880-915, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26150582